Verastem, Inc. — Q2 2015 Form 10-Q Summary
Business context and reporting period
Verastem is a clinical-stage biopharmaceutical company developing cancer therapies targeting cancer stem cells, primarily through FAK and PI3K/mTOR pathways. The filing covers the quarter and six months ended June 30, 2015. Lead candidate VS-6063 was being evaluated in multiple mesothelioma, ovarian cancer, and non-small-cell lung cancer studies; VS-4718 and VS-5584 were in Phase 1 trials.
The company had not generated revenue and remained dependent on equity financing to fund operations.
Financial position and key metrics
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $11.0 million, versus $8.3 million | $21.6 million, versus $16.7 million |
| General and administrative expense | $4.4 million, versus $4.8 million | $9.1 million, versus $9.5 million |
| Net loss | $15.4 million, versus $13.0 million | $30.6 million, versus $26.1 million |
| Net loss per share | $0.42, versus $0.51 | $0.87, versus $1.02 |
| Cash used in operating activities | Not separately provided | $23.7 million, versus $18.0 million |
At June 30, 2015, cash and cash equivalents were $35.2 million, short-term investments were $96.9 million, and total cash, cash equivalents, and investments were $132.1 million. Current liabilities were $9.8 million, with no debt reported. Total stockholders’ equity was $125.3 million, and accumulated deficit was $171.6 million.
Operating and profit margins were not meaningful because the company had no revenue and reported operating losses. Stock-based compensation expense was $5.7 million for the first six months of 2015.
Material changes versus the prior comparable period
- Second-quarter research and development expense increased $2.7 million, primarily due to higher contract research organization costs and personnel costs.
- First-half research and development expense increased $4.9 million, primarily due to higher outsourced development and clinical-trial costs and increased personnel costs.
- Second-quarter net loss increased $2.4 million, while first-half net loss increased $4.5 million.
- Cash used in operating activities increased $5.8 million in the first half, reflecting increased clinical development spending.
- Total cash, cash equivalents, and investments increased from $92.7 million at December 31, 2014 to $132.1 million at June 30, 2015.
- The company raised approximately $50.9 million in net proceeds from a January 2015 public offering and approximately $10.7 million from its at-the-market program during the first half of 2015. Total financing cash inflows were $63.7 million.
- Shares outstanding increased to 36.9 million as of August 5, 2015, from 27.3 million at December 31, 2014, primarily reflecting equity financing activity.
Guidance, outlook, risks, and unusual items
Management expected existing cash, cash equivalents, and investments to fund the current operating plan and capital requirements into the first half of 2017, subject to assumptions that could prove incorrect. The company expected operating expenses and losses to increase as clinical trials and development programs advance.
Management anticipated a COMMAND trial interim analysis during the third quarter of 2015, additional VS-6063 clinical updates in the second half of 2015, preliminary data from a mesothelioma extended-treatment cohort in the first half of 2016, and results from VS-4718 and VS-5584 Phase 1 trials in the second half of 2015.
Key risks include clinical-trial enrollment, safety and efficacy outcomes, regulatory approval, development costs and timing, intellectual-property protection, reliance on third parties, competition, and the need for substantial additional capital. The company had no committed external funding source and stated that additional equity or debt financing, collaborations, or licensing arrangements might be required. Future equity financing could dilute existing stockholders.
There were no material subsequent events, legal proceedings, material changes to contractual obligations, or off-balance-sheet arrangements reported. Management concluded that disclosure controls and procedures were effective as of June 30, 2015.
Important facts for investors to verify
- Whether the company’s cash runway remained consistent with the stated expectation of funding operations into the first half of 2017.
- Results and statistical significance of the COMMAND interim analysis and subsequent regulatory strategy for VS-6063.
- Progress, enrollment, safety data, and costs across the VS-6063, VS-4718, and VS-5584 programs.
- The pace of operating cash burn and whether research and development spending continued to increase.
- The company’s ability to obtain additional financing without significant dilution or unfavorable terms.
- Any subsequent changes in patent rights, licensing arrangements, trial design, or regulatory status.